Trial · NCT05361655
Results by group31
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 31
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in Postmenopausal Female or Male Participants With Metastatic Breast Cancer | Palbociclib + Aromatase Inhibitor | 49.1 | 95% Confidence Interval 45.2 to 57.7 | Months | |
| Overall Survival (OS) in Postmenopausal Female or Male Participants With Metastatic Breast Cancer | Aromatase Inhibitor | 43.2 | 95% Confidence Interval 37.6 to 48.0 | Months | |
| Real-World Progression Free Survival (rwPFS) in Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Palbociclib + Aromatase Inhibitor | 19.3 | 95% Confidence Interval 17.5 to 20.7 | Months | |
| Real-World Progression Free Survival (rwPFS) in Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Aromatase Inhibitor | 13.9 | 95% Confidence Interval 12.5 to 15.2 | Months | |
| Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Palbociclib + Aromatase Inhibitor | Complete response | 163 | Participants | |
| Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Aromatase Inhibitor | Complete response | 86 | Participants | |
| Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Palbociclib + Aromatase Inhibitor | Partial response | 569 | Participants | |
| Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Aromatase Inhibitor | Partial response | 300 | Participants | |
| Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Palbociclib + Aromatase Inhibitor | Stable disease | 350 | Participants | |
| Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Aromatase Inhibitor | Stable disease | 273 | Participants | |
| Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Palbociclib + Aromatase Inhibitor | Progressive disease | 155 | Participants | |
| Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Aromatase Inhibitor | Progressive disease | 260 | Participants | |
| Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Palbociclib + Aromatase Inhibitor | Indeterminate response | 26 | Participants | |
| Number of Participants According to Real-World Tumor Responses (rwTR): Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Aromatase Inhibitor | Indeterminate response | 69 | Participants | |
| Real-World Response Rate (rwTR) in Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Palbociclib + Aromatase Inhibitor | 57.98 | Percentage of participants | ||
| Real-World Response Rate (rwTR) in Postmenopausal Female or in Male Participants With Metastatic Breast Cancer | Aromatase Inhibitor | 39.04 | Percentage of participants | ||
| Number of Participants According to Initial Dose of Palbociclib: Palbociclib + Aromatase Inhibitor Arm Only | Palbociclib + Aromatase Inhibitor | Palbociclib 75 mg/day | 48 | Participants | |
| Number of Participants According to Initial Dose of Palbociclib: Palbociclib + Aromatase Inhibitor Arm Only | Palbociclib + Aromatase Inhibitor | Palbociclib 125 mg/day | 1110 | Participants | |
| Number of Participants According to Initial Dose of Palbociclib: Palbociclib + Aromatase Inhibitor Arm Only | Palbociclib + Aromatase Inhibitor | Palbociclib 100 mg/day | 144 | Participants | |
| Number of Participants According to Initial Dose of Palbociclib: Palbociclib + Aromatase Inhibitor Arm Only | Palbociclib + Aromatase Inhibitor | Missing | 22 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05361655/results